Recombinant Phospho-p53 (Ser46) Monoclonal Antibody (AN301140L)

For research use only.
Verified Samples |
Verified Samples in WB: HEK293 Verified Samples in IHC: Human breast carcinoma |
Dilution | IHC 1:200-1:1000, WB 1:2000-1:10000 |
Isotype | IgG,κ |
Host | Rabbit |
Reactivity | Human, Mouse |
Applications | WB, IHC |
Clonality | Monoclonal;Recombinant |
Immunogen | A synthetic peptide corresponding to residues around (Ser46) of Human Phospho-p53 |
Abbre | p53 |
Synonyms | BCC, LFS, TRP, BMFS, Antigen NY-CO, Tumor protein, Phosphoprotein p, Tumor suppressor p, Mutant tumor protein, Cellular tumor antigen p, Transformation related protein, BCC7, LFS1, P53, TRP53, TP53, BMFS5, Antigen NY-CO-13, Cellular tumor antigen p53, FLJ92943, Mutant tumor protein 53, p53 tumor suppressor, Phosphoprotein p53, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, BCC7, LFS1, P53, TRP53, tumor protein p53, Antigen NY-CO-13, BCC7, Cellular tumor antigen p53, FLJ92943, LFS1, Mutant tumor protein 53, p53, p53 tumor suppressor, P53, Phosphoprotein p53, Tp53, Transformation related protein 53, TRP53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53 |
Swissprot | |
Calculated MW | 44 kDa |
Observed MW |
53 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
Cellular Localization | Nuclear |
Concentration | 0.2 mg/mL |
Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
Purification Method | Protein A |
Research Areas | Cell Biology, Epigenetics and Nuclear Signaling, Cancer |
Clone No. | 6H1 |
Conjugation | Unconjugated |
Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
Shipping | Ice bag |
background | TP53(tumor protein p53) Homo sapiens This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.:{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.:{{item.cat}}
{{index}} {{goods_show_value}}
-
IF:{{item.impact}}
Journal:{{item.journal}} ({{item.year}})
DOI:{{item.doi}}Reactivity:{{item.species}}
Sample Type:{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
